Condition: Treatment Resistant Depression (TRD) · Sponsor: Assistance Publique - Hôpitaux de Paris
Depression is a common illness, affecting 17% of the population over the course of a lifetime. A third of depressions relapses and progresses to recurrence and resistance to treatments. Despite the optimization of antidepressant medical strategies, 20 to 40% of depressions do not respond to treatment. This is particularly worrying as 6% of non-responder patients will die by committing suicide. Depression has a major impact on quality of life, socio-professional functioning and healthcare consumption. Sometimes, TRD is part of a bipolar illness. In this case, the challenge is even bigger because antidepressants are no well tolerated, further reducing the therapeutic options in case of resistance, the severity and duration of the depressive episodes are the main factors explaining the deterioration of the quality of life and the increasing cost of cares for these patients. The standard treatment for TRD is electroconvulsive therapy (ECT), which results in a response in 60 to 70% of cases after a few weeks of treatment. However, the improvement is often transient and 40% of patients relapse within 6 months of the initial ECT session. Moreover, ECT is often not well tolerated. This therapeutic impasse therefore makes TRD a priority public health target to which it is urgent to provide a realistic medico-economical response. The literature suggests that Vagus Nerve Stimulation (VNS) has unique kinetics of efficacy in depression, particularly in preventing long-term recurrences…
This description comes directly from the study's public registry record.
Philippe DOMENECH, MD, MSc · (0) 1 45 65 76 65 · philippe.domenech@ghu-paris.fr
Fabien VINCKIER, MD, MSc · (0) 1 45 65 84 52 · f.vinckier@ghu-paris.fr
Always discuss trial participation with your own doctor first.
| CHU Angers | Angers, France, France | Active Not Recruiting |
| Centre Hospitalier Charles Perrens | Bordeaux, France, France | Recruiting |
| CHU Caen | Caen, France, France | Not Yet Recruiting |
| CHU Clermont-Ferrand, Hôpital Gabriel Montpied | Clermont-Ferrand, France, France | Recruiting |
| AP-HP. Nord - Université de Paris, Hôpital Louis Mourier | Colombes, France, France | Withdrawn |
| APHP. Hôpitaux Universitaires Henri Mondor, Hôpital Henri Mondor | Créteil, France, France | Recruiting |
| CHU Dijon, Hôpital Le Bocage | Dijon, France, France | Recruiting |
| CHU Grenoble Alpes | Grenoble, France, France | Recruiting |
| AP-HP. Université Paris Saclay, Hôpital Bicêtre | Le Kremlin-Bicêtre, France, France | Withdrawn |
| CHU Lille | Lille, France, France | Recruiting |
| Hospices Civils de Lyon, Hôpital Pierre Wertheimer | Lyon, France, France | Not Yet Recruiting |
| Assistance Publique Hôpitaux de Marseille, Hôpital de la Conception | Marseille, France, France | Not Yet Recruiting |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05952674